RECRUITINGOBSERVATIONAL
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
About This Trial
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
Who May Be Eligible (Plain English)
Who May Qualify:
Female patients meeting the following criteria will be eligible for study enrollment:
1. Patients with Fabry disease who are pregnant and/or breastfeeding, whether or not they are exposed to migalastat
2. Able and willing to provide willing to sign a consent form or assent, if applicable.
3. Able and willing to provide HCP contact information.
Who Should NOT Join This Trial:
None
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Female patients meeting the following criteria will be eligible for study enrollment:
1. Patients with Fabry disease who are pregnant and/or breastfeeding, whether or not they are exposed to migalastat
2. Able and willing to provide informed consent or assent, if applicable.
3. Able and willing to provide HCP contact information.
Exclusion Criteria:
None
Treatments Being Tested
DRUG
migalastat
This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
Locations (1)
Amicus Therapeutics, Inc. Pregnancy Registry
Philadelphia, Pennsylvania, United States